Rainier Therapeutics

📍 San Leandro, United States👥 2 employees💰 Last funded Jun 2019
Pharmaceutical Manufacturing🌐 rainierrx.com
Website LinkedIn
Rainier Therapeutics is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Netherlands
1
Investor activity2016–2019 · investors recorded per year
2016220191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Rainier Therapeutics?
Rainier Therapeutics has 3 investors on record on gritt.io.
When did Rainier Therapeutics last raise funding?
The most recent investment in Rainier Therapeutics recorded on gritt.io was in June 2019.
What industry is Rainier Therapeutics in?
Rainier Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Rainier Therapeutics based?
Rainier Therapeutics is headquartered in San Leandro, United States.